Insulin Delivery Systems Market Analysis (2007-2010)

1. Analyst View

2. Diabetes Disease Indicator

3. Diabetes & Obesity

4. Global Market Analysis

• 4.1 Global Diabetes Drugs Market
• 4.2 Global Insulin Market
  • 4.2.1 India
    • 4.2.1.1 Prevalence
    • 4.2.1.2 Market Analysis
  • 4.2.2 China
    • 4.2.2.1 Prevalence
    • 4.2.2.2 Market Analysis
  • 4.2.3 US
    • 4.2.3.1 Prevalence
    • 4.2.3.2 Market Analysis
  • 4.2.4 Russia
    • 4.2.4.1 Prevalence
    • 4.2.4.2 Market Analysis
  • 4.2.5 Japan
    • 4.2.5.1 Prevalence
    • 4.2.5.2 Market A+G1nalysis
  • 4.2.6 Germany
    • 4.2.6.1 Prevalence
    • 4.2.6.2 Market Analysis
  • 4.2.7 Pakistan
    • 4.2.7.1 Prevalence
    • 4.2.7.2 Market Analysis
  • 4.2.8 Brazil
    • 4.2.8.1 Prevalence
    • 4.2.8.2 Market Analysis
  • 4.2.9 Mexico
    • 4.2.9.1 Prevalence
  • 4.2.10 Egypt
    • 4.2.10.1 Prevalence

5. Insulin Delivery Devices

• 5.1 Present Devices
  • 5.1.1 Insulin Pens
    • 5.1.1.1 Mechanism & Technologies
    • 5.1.1.2 Market Analysis
      • 5.1.1.2.1 Global
      • 5.1.1.2.2 US
      • 5.1.1.2.3 Europe
      • 5.1.1.2.4 Japan
    • 5.1.1.3 Pros & Cons
    • 5.1.1.4 Key Players
  • 5.1.2 Insulin Pumps
    • 5.1.2.1 Mechanism & Technologies
    • 5.1.2.2 Market Analysis
      • 5.1.2.2.1 Global
      • 5.1.2.2.2 US
      • 5.1.2.2.3 Non US
    • 5.1.2.3 Pros & Cons
    • 5.1.2.4 Key Players
  • 5.1.3 Inhaled Insulin
    • 5.1.3.1 Mechanism & Technologies
    • 5.1.3.2 Market Analysis
      • 5.1.3.2.1 Exubera Lackluster Performance
      • 5.1.3.2.2 Why Exubera Failed?
        • 5.1.3.2.2.1 Poor Preparation for Product Launching
        • 5.1.3.2.2.2 Insurance Reimbursements
        • 5.1.3.2.2.3 Lack of Market Understanding for this Product
        • 5.1.3.2.2.4 Effectiveness of Other Diabetes Treatments
        • 5.1.3.2.2.5 Lack of Safety Data & Health-related Problems
        • 5.1.3.2.2.6 Poor Design & Other Inconveniences
    • 5.1.3.3 Pros & Cons
    • 5.1.3.4 Projections & Future of Other Inhalable Insulin
  • 5.1.4 Insulin Syringes
    • 5.1.4.1 Mechanism & Technology
    • 5.1.4.2 Market Analysis
    • 5.1.4.3 Pros & Cons
    • 5.1.4.4 Future Outlook (2007-2010)
  • 5.1.5 Insulin Jet Injectors
    • 5.1.5.1 Mechanism & Technologies
    • 5.1.5.2 Market Analysis
    • 5.1.5.3 Pros & Cons
    • 5.1.5.4 Future Outlook (2007-2010)
• 5.2 Future Devices
  • 5.2.1 Oral Insulin
  • 5.2.2 Insulin Patch
  • 5.2.3 Implantable Insulin Pumps

6. Industry Analysis

• 6.1 Drivers
  • 6.1.1 Increasing Number of Diabetic Patients
  • 6.1.2 Convenient & Less Painful Modes of Insulin Delivery
  • 6.1.3 Improved Access & Lower Insulin Prices in the Developing World
  • 6.1.4 Early Diagnosis & Increasing Awareness for Treatment
  • 6.1.5 Government Support
• 6.2 Challenges
  • 6.2.1 High R&D & Production Cost
  • 6.2.2 Long Time to Market
  • 6.2.3 Poverty
  • 6.2.4 Insurance Reimbursement
  • 6.2.5 Traditional Treatments
  • 6.2.6 High Cost of Insulin Inhalers
  • 6.2.7 Rapidly Changing Technology
• 6.3 Opportunities
  • 6.3.1 US & Developing Countries - Potential Markets for Insulin Syringes
  • 6.3.2 Europe & Japan - Potential Markets for Pen Devices
  • 6.3.3 Developed World - Potential Market Oral Insulin
  • 6.3.4 US - Potential Market for Insulin Pumps

7. Future Outlook

• 7.1 Global Diabetes Drug Market (2007-2012)

8. Key Players

• 8.1 Eli Lilly & Company
• 8.2 Novo Nordisk A/S
• 8.3 Sanofi-Aventis
• 8.4 Becton, Dickinson and Company
• 8.5 Medtronic, Inc.

• Figure 3-1: Global - Overweight & Obese Population (in Billion), 2005, 2007E & 2015E
• Figure 4-1: Global - Number of Diabetic Patients (in Million), 2003 & 2007
• Figure 4-2: Global - Diabetes Drugs Market (in Billion US$), 2004-2006
• Figure 4-3: Global - Insulin Market (in Billion US$), 2005 & 2006
• Figure 4-4: India - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-5: India - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-6: India - Insulin Market (in Billion INR), 2003 & 2006
• Figure 4-7: India - Share of Key Players in Insulin Market (%), 2004
• Figure 4-8: China - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-9: China - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-10: China - Insulin Market (in Billion RMB), 2005, 2006E & 2012F
• Figure 4-11: China - Share of Key Players in Insulin Market (%), 2004*
• Figure 4-12: US - Diabetic Patients in Age Group 20-79 Years (in ‘000), 2003-2006E
• Figure 4-13: US - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-14: US - Insulin Market (in Billion US$), 2003-2006E
• Figure 4-15: US - Share of Key Players in Insulin Market (%), 2006
• Figure 4-16: Russia - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-17: Russia - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-18: Russia - Insulin Market (in Million US$), 2005-2008E
• Figure 4-19: Russia - Share of Key Players in Insulin Market (%), 2005
• Figure 4-20: Russia - Share of Sales Channel in Insulin Market (%), 2005
• Figure 4-21: Japan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-22: Japan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-23: Japan - Insulin Market (in Billion JPY), 2004-2006E & 2012F
• Figure 4-24: Japan - Share of Novo Nordisk in Insulin Market (%), 2006*
• Figure 4-25: Germany - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-26: Germany - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-27: Germany - Insulin Market (in Billion US$), 2005-2007E
• Figure 4-28: Pakistan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-29: Pakistan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-30: Brazil - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-31: Brazil - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-32: Brazil - Insulin Market (in Million US$), 2000E, 2006 & 2010E
• Figure 4-33: Mexico - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-34: Mexico - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-35: Egypt - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-36: Egypt - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 5-1: Global, US, Europe & Japan - Insulin Units Delivered through Pen Devices (%), 2006
• Figure 5-2: US - Insulin Pen Devices Market (in Million US$), 2003-2006E
• Figure 5-3: US - Insulin Pen Devices Market (in Million US$), 2007-2010F
• Figure 5-4: US - Insulin Units Delivered through Pen Devices (%), 1996, 2000, 2004 & 2006
• Figure 5-5: US - Volume Share of Disposable & Refillable Pen Devices (%), 2006
• Figure 5-6: Europe - Insulin Units Delivered through Pen Devices (%), 1996, 2000, 2004 & 2006
• Figure 5-7: Europe - Volume Share of Disposable & Refillable Pen Devices (%), 2006
• Figure 5-8: Japan - Insulin Units Delivered through Pen Devices (%), 1996, 2000, 2004 & 2006
• Figure 5-9: Global - Share of Key Players in Pen Devices Market (%), 2005
• Figure 5-10: Global - Insulin Pumps & Disposables Market (in Million US$), 2002-2006E
• Figure 5-11: Global - Insulin Pumps & Disposables Market (in Million US$), 2007-2009F
• Figure 5-12: Global - Share of US & Non-US Markets in Insulin Pumps & Disposables Market (%), 2002-2006E
• Figure 5-13: Global - Share of US & Non-US Markets in Insulin Pumps & Disposables Market (%), 2007-2009F
• Figure 5-14: US - Insulin Pumps & Disposables Market (in Million US$), 2002-2006E
• Figure 5-15: US - Insulin Pumps & Disposables Market (in Million US$), 2007-2009F
• Figure 5-16: US - Share of Insulin Pumps & Disposables in Market (%), 2002-2006E
• Figure 5-17: US - Share of Insulin Pumps & Disposables in Market (%), 2007-2009F
• Figure 5-18: US - Sales of Insulin Pumps (in ‘000 Units), 2002-2006E
• Figure 5-19: US - Sales of Insulin Pumps (in ‘000 Units), 2007-2009F
• Figure 5-20: US - Sales of New & Replacement Insulin Pumps (in ‘000 Units), 2002-2006E
• Figure 5-21: US - Sales of New & Replacement Insulin Pumps (in ‘000 Units), 2007-2009F
• Figure 5-22: US - Cumulative Sales of New Insulin Pumps (in ‘000 Units) 2007-2009F
• Figure 5-23: US - Cumulative Sales of New Insulin Pumps for Type 1 & Type 2 Patients (in ‘000 Units), 2002-2006E
• Figure 5-24: US - Cumulative Sales of New Insulin Pumps for Type 1 & Type 2 Patients (in ‘000 Units), 2007-2009F
• Figure 5-25: US - Cumulative Penetration of Type 1 & Type 2 Patients using Insulin Pumps (%), 2002-2006E
• Figure 5-26: US - Cumulative Penetration of Type 1 & Type 2 Patients using Insulin Pumps (%), 2007-2009F
• Figure 5-27: US - Users Discontinuing Use of Insulin Pumps (%), 2002-2006E
• Figure 5-28: US - Users Discontinuing Use of Insulin Pumps (%), 2007-2009F
• Figure 5-29: Non-US - Insulin Pumps & Disposables Market (in Million US$), 2002-2006E
• Figure 5-30: Non-US - Insulin Pumps & Disposables Market (in Million US$), 2007-2009F
• Figure 5-31: Global - Share of Key Players in Insulin Pumps Market (%), 2002-2006E
• Figure 5-32: Global - Share of Key Players in Insulin Pumps Market (%), 2007-2009F
• Figure 5-33: US - Share of Key Players in Insulin Pumps Market (%), 2002-2006E
• Figure 5-34: US - Share of Key Players in Insulin Pumps Market (%), 2007-2009F
• Figure 5-35: Europe - Share of Key Players in Insulin Pumps Market (%), 2004
• Figure 5-36: Japan - Share of Nipro in Insulin Pumps Market (%), 2005
• Figure 5-37: Global - Sales of Exubera (in Million US$), 2006*, 2007** & 2015F
• Figure 5-38: Global - Forecast for Sales of Exubera, Technosphere, Air System & Aerx-iDMS (in Million US$), 2015
• Figure 5-39: Global - Forecast for Share of Inhalable Insulin (%), 2015
• Figure 5-40: US - Insulin Syringes Market (in Million US$), 2003-2006E
• Figure 5-41: US - Share of Insulin Syringes Market (%), 2003-2006E
• Figure 5-42: US - Forecast for Insulin Syringes Market (in Million US$), 2007-2010
• Figure 5-43: US - Forecast for Share of Insulin Syringes Market (%), 2007-2010
• Figure 5-44: Global - Jet Injectors & Insulin-driven Jet Injectors Market (in Million US$), 2003-2006E
• Figure 5-45: US - Insulin-driven Jet Injectors Market (in Million US$), 2003-2006E
• Figure 5-46: US - Share of Insulin-driven Jet Injectors Market (%), 2003-2006E
• Figure 5-47: Global - Forecast for Insulin-driven Jet Injectors Market (in Million US$), 2007-2010
• Figure 5-48: US - Forecast for Insulin-driven Jet Injectors Market (in Million US$), 2007-2010
• Figure 5-49: US - Forecast for Share of Insulin-driven Jet Injectors Market (%), 2007-2010
• Figure 7-1: Global - Forecast for Number of Diabetic Patients (in Million), 2013, 2019 & 2025
• Figure 7-2: Global - Forecast for Diabetes Drugs Market (in Billion US$), 2007-2012
• Figure 7-3: Global - Forecast for Insulin Market (in Billion US$), 2007-2012
• Figure 7-4: Global - Insulin Demand (in Kg), 2006 & 2012F

• Table 2-1: Global - Top 10 Countries with Maximum Diabetic Population in Age Group 20-79 Years (in Million), 2003 & 2025F
• Table 3-1: Global - Percentage of Overweight Population by Leading Countries (2006)
• Table 3-2: Global - Percentage of Diabetic Population by Leading Countries (2003)
• Table 4-1: Global - List of Top 10 Anti-diabetic Brands, 2005
• Table 4-2: India - Diabetic Patients in Age Group 20-79 Years (in ‘000), 2003
• Table 4-3: India - Forecast for Diabetic Patients in Age Group 20-79 Years (in ‘000), 2025
• Table 4-4: China - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-5: China - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-6: US - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-7: US - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-8: Russia - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-9: Russia - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-10: Japan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-11: Japan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-12: Germany - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-13: Germany - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-14: Pakistan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-15: Pakistan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-16: Brazil - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-17: Brazil - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-18: Mexico - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-19: Mexico - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-20: Egypt - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-21: Egypt - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 5-1: Characteristics of Various Inhalable Insulin Products
• Table 8-1: Eli Lilly & Company - Key Financials (in Million US$), 2004-2006
• Table 8-2: Novo Nordisk A/S - Key Financials (in Million US$), 2004-2006
• Table 8-3: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
• Table 8-4: Becton, Dickinson and Company - Key Financials (in Million US$), 2005-2007
• Table 8-5: Medtronic, Inc. - Key Financials (in Million US$), 2005-2007